FOI 9583 – Q2

Q2. How many patients were treated for **severe asthma**, **COPD**, **CRwNP** with the following medicines in the 3 months between the start of April 2026 and end of June 2026?

Name of medicine	**Severe asthma** (please include all types or references to asthma)	**Chronic Obstructive Pulmonary Disease** (COPD)	**Chronic rhinosinusitis with nasal polyps** (CRwNP)
2.1 Benralizumab (Fasenra)	0		
2.2 Depemokimab (Exdensur)	0		0
2.3 Dupilumab (Dupixent)	0	0	0
2.4 Mepolizumab (Nucala)	0	0	0
2.5 Omalizumab (Xolair)	0		0
2.6 Reslizumab (Cinqaero)	0		
2.7 Tezepelumab (Tezspire)	0		0